The flu vaccine is a must for anyone over 60. Influenza can be more severe in older adults, often leading to complications like pneumonia. According to the Centers for Disease Control and Prevention ...

Anticipated growth for ‘Saudi Arabia 23 Valent Pneumococcal Polysaccharide Vaccine Market’ is significant from 2024 to 2032. The market showed steady growth in 2024 and is expected to continue rising ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

3 According to the World Health Organization, there are two classes of pneumococcal vaccines currently available, with one based on olysaccharides and the other based on polysaccharides conjugated to ...

Sanofi and SK bioscience have entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license and commercialize next-generation PCVs for both ...

The pneumococcal polysaccharide vaccine (PPV) is currently recommended for older adults and high-risk subjects, including patients with chronic obstructive pulmonary disease (COPD) and asthma.

The CDC currently recommends pneumococcal vaccination for all adults age 65 ... MSD also sells an older shot called Pneumovax 23, which covers 23 serotypes, but is based on an older polysaccharide ...

Respiratory virus season has arrived, and hopefully you’re up to date on vaccinations that can help prevent infectious diseases including COVID, the flu, whooping cough, and respiratory syncytial ...

Table 2. A Provision of Aggregate and Serotype-Specific Vaccine Efficacy at Different Time Points Postvaccination and Model Coefficient Estimates VE C, % (95% CrI) at Several Time Points After ...

Vaccines protect babies and children from potentially life-threatening diseases. Widespread childhood vaccination has reduced or eliminated deadly diseases like polio and smallpox. Vaccines currently ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...